TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05869630

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Programme
Description: All patients were informed about knee OA, joint protection principles, and the exercise effects on knee OA before treatment. The exercises were supervised by a physiotherapist for 30 minutes twice a week and once a week as a home program. The exercise program consisted of a warm-up, strengthening knee extensors and lower extremity stretching exercises. Firstly, quadriceps isometric and adductor isometric (roll tightening) exercises, hamstring stretching, quadriceps stretching, and gastrocnemius stretching were applied. Then, hip flexion-extension-abduction-adduction, and knee extension while sitting were applied with exercise bands. Strengthening exercises were composed of three sets with 10 repetitions. Stretching exercises were performed 10 repetitions for 10 seconds.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experiments
Description: The total RNA was isolated from peripheral blood samples taken from patients and the control group by applying the protocol of the manufacturer (LucigenMasterPure™ Complete DNA and RNA Purification Kit, USA). The total RNA was isolated in three steps: Lysis stage of the whole blood samples, precipitation of nucleic acids and precipitation of total RNA. The purity and concentration of the isolated total RNA samples were measured with the spectrophotometer (Thermo Fischer) device. The samples were stored at -80°C until the next step. To determine the microRNA expression levels; firstly, conjugate DNA (cDNA) was synthesized from total RNA samples according to the manufacturer's protocol. Whether the desired region reproduced in the reaction and whether there were primer dimers were checked by adding a melting curve step. In addition, blood samples of 30 age-sex matched healthy volunteers were compared.
Study: NCT00743275

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Split, Inactivated, Trivalent Influenza vaccine (Fluzone®)
Description: 0.5 mL, intramuscular
Study: NCT03195738

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to Occupational Performance (CO-OP)
Description: In the CO-OP intervention participants are first assisted to identify 3-5 occupation based goals which then become the focus of the intervention sessions. Over the course of the 10 intervention sessions, participants are guided to learn and practice problem solving using a metacognitive strategy, Goal-Plan-Do-Check applied to their self-identified goals. Study therapists use 'guided discovery' an iterative technique to facilitate problem solving by the participant to develop plans to work toward their goals and to evaluate their progress. Intervention takes place in the location that is most meaningful for the participant's selected goal (e.g. home, school, playground etc.). Participants are provided with a work book to track progress.
Study: NCT03732313

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Central toenail resection
Description: Using local aneasthesia, resection of central part of toenail with germinal matrix.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wedge toenail resection
Description: Using local anaesthesia,we remove lateral part of toenail .
Study: NCT01236248

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevention
Description: 9-session computerized cognitive behavioral program that young girls and their mothers interact with on a weekly basis in the privacy of their home. Girls and their mothers will watch and interact with 10 compact disc (CD) intervention sessions to learn skills to help girls avoid substance use.
Study: NCT02966392

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tracoe cuff pressure controller
Description: Participant will be attached to the cuff pressure controller as soon as possible after enrolment. They will remain attached during their intubated stay. If reintubated during same admission they will continue in the intervention arm. If readmitted to ICU they will be managed according to standard care.
Study: NCT03538249

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic and Inspiratory training
Study: NCT01185210

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo (mix of sugar and salt) 20 minutes before consuming fructose.
Study: NCT03538249

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined
Description: Aerobic, inspiratory and resistance training
Study: NCT03849950

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMARTCare
Description: 1. Ambulatory nurses will undertake 4 hours of training consistent with the evidenced-based guidelines for SMS in routine care.~2. An education program for patients in the intervention arm that targets training in core self-management skills and is comprised of an introduction and 5 education modules.~3. An introductory call from a health coach prior to initiating treatment and 5 subsequent calls: prior to the first dose of treatment; 7-14 days following the first dose of treatment; within 2 weeks of coaching session 2; and timing is flexible for the last 2 sessions, but to be completed within 4 months following the first dose of treatment.~4. Optional sub-study: A sub-set of patients will participate in an end of study interview to gain further insight into SMARTCare.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: 1. Ambulatory nurses will undertake 4 hours of training consistent with the evidenced-based guidelines for SMS in routine care.
Study: NCT04784260

Intervention type: OTHER
Intervention: Microbiome analysis
Description: Evaluate the bacterial composition in sperm from the different groups

Intervention type: OTHER
Intervention: Microbiome analysis
Description: Evaluate the bacterial composition in sperm from the different groups
Study: NCT02577731

Intervention type: OTHER
Group type: OTHER
Intervention: Bone marrow collection
Description: Bone marrow will be collected from the patient at time of orthopedic repair in the operating room. A second sample may be collected if the patient is required to return to the operating room for further repair of orthopedic injury.

Intervention type: OTHER
Group type: OTHER
Intervention: Bone marrow collection
Description: Bone marrow will be collected from the patient at time of orthopedic repair in the operating room. A second sample may be collected if the patient is required to return to the operating room for further repair of orthopedic injury.

Intervention type: OTHER
Group type: OTHER
Intervention: Bone marrow collection
Description: Bone marrow will be collected from the patient at time of orthopedic repair in the operating room. A second sample may be collected if the patient is required to return to the operating room for further repair of orthopedic injury.

Intervention type: OTHER
Group type: OTHER
Intervention: Blood collection
Description: Blood sample collection will be collected from the patient at time of orthopedic repair in the operating room. A second sample may be collected if the patient is required to return to the operating room for further repair of orthopedic injury.

Intervention type: OTHER
Group type: OTHER
Intervention: Blood collection
Description: Blood sample collection will be collected from the patient at time of orthopedic repair in the operating room. A second sample may be collected if the patient is required to return to the operating room for further repair of orthopedic injury.

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical data collection
Description: Clinical data collection will encompass demographic information, past and present medical records, laboratory, microbiology, and all other test results, x-ray, CT, MRI, US and all other imaging test results, records about any medication received during admission, records of physical exam during admission, records of all vital signs and hemodynamic monitoring during admission, records of any procedure or intervention during admission, records of any procedure or intervention during hospital admission, condition at the discharge and discharge facility.

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical data collection
Description: Clinical data collection will encompass demographic information, past and present medical records, laboratory, microbiology, and all other test results, x-ray, CT, MRI, US and all other imaging test results, records about any medication received during admission, records of physical exam during admission, records of all vital signs and hemodynamic monitoring during admission, records of any procedure or intervention during admission, records of any procedure or intervention during hospital admission, condition at the discharge and discharge facility.
Study: NCT02539537

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluoro-uracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-folinic
Study: NCT04675021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6094 (Savolitinib) film coated tablets 600 mg
Description: AZD6094 (Savolitinib) ilm Coated Tablet 200 mg x 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-AZD6094 (Savolitinib) Solution for Infusion, 20 μg/mL (NMT 37.0 kBq/5 mL)
Description: 14C AZD6094 (Savolitinib) Solution for Infusion (20 μg/mL (NMT 37.0 kBq/5 mL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] AZD6094 (Savolitinib) Oral Solution, 300 mg (NMT 4.1 MBq)
Description: 14CAZD6094 (Savolitinib) Oral Solution (300 mg NMT 4.1MBq)
Study: NCT04364854

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SET (Speech Entrainment Therapy) 3 weeks
Description: 3 weeks of SET which consists of practicing fluent speech in real time with an audio-visual computer program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SET (Speech Entrainment Therapy) 4.5 weeks
Description: 4.5 weeks of SET which consists of practicing fluent speech in real time with an audio-visual computer program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SET (Speech Entrainment Therapy) 6 weeks
Description: 6 weeks of SET which consists of practicing fluent speech in real time with an audio-visual computer program

Intervention type: OTHER
Group type: OTHER
Intervention: No Therapy 6 Weeks
Description: Participants will not be getting any SET for 6 weeks
Study: NCT00567710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL - 1020
Description: 10 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL - 1020
Description: BL 1020 20-30 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Capsules
Study: NCT00733993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine 150 MG
Description: Across five separate testing days, subjects were administered two placebo doses, 20 mg amphetamine, 150 mg caffeine, and 300 mg caffeine in counterbalanced fashion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Across five separate testing days, subjects were administered two placebo doses, 20 mg amphetamine, 150 mg caffeine, and 300 mg caffeine in counterbalanced fashion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphetamine
Description: Across five separate testing days, subjects were administered two placebo doses, 20 mg damphetamine,150 mg caffeine, and 300 mg caffeine in counterbalanced fashion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine 300 MG
Description: Across five separate testing days, subjects were administered two placebo doses, 20 mg damphetamine,150 mg caffeine, and 300 mg caffeine in counterbalanced fashion
Study: NCT01281150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study: NCT01185210

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alanine
Description: Subjects will receive 12.5 grams of alanine 20 minutes before consuming fructose.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alanine
Description: Subjects will receive 25 grams of alanine 20 minutes before consuming fructose.
Study: NCT02620748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Study: NCT03074513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT04032301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Six infusions of intravenous 0.5 mg/kg ketamine hydrochloride solution over 3 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Six infusions of intravenous normal saline solution over 3 weeks.
Study: NCT04225897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV521
Description: RV521 is an RSV F protein inhibitor administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: vehicle administered orally
Study: NCT02115048

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Study: NCT03722238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg Immediate Release/Extended Release Caplet
Description: Ibuprofen 600 mg Immediate Release/Extended Release Tablet to be adminstered orally (i.e., one caplet every 12 hours, not to exceed 2 caplets per day) for pain.
Study: NCT03603353

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS (vaporizer/e-cig) and smoking cessation counseling
Description: Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling.~Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation counseling
Description: Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
Study: NCT01269021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil plus lower dose of Prednisone
Description: MMF 1.0-1.5g/d\*6mons Prednisone 0.4-0.6 mg/kg/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone in full dose
Description: 0.8-1mg/kg/d
Study: NCT02476253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate
Description: Intravenous 4.2% Sodium Bicarbonate 125ml to 250ml / 30min up to 1000ml/24h to maintain plasma pH equal or greater than 7.30
Study: NCT04417517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: evorpacept
Description: Fusion protein that blocks CD47-SIRPalpha pathway

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azacitidine
Description: Hypomethylating agent (HMA)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Hypomethylating agent (HMA)
Study: NCT01539421

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of Home exercise computer program
Description: After a 30-minute rest period the study patient performed a series of 4 representative exercises from the Wii under direct supervision by an investigator. Five minutes' rest was allotted between each exercise. The patient was instructed to exercise at his/her own pace, with a maximal duration of 5 minutes per exercise. The Oxycon Mobile was worn throughout this exercise, and the metabolic measurements listed above were recorded over the last 30 seconds of each exercise. The exercises included running in place, upper arm movements, stepping in place, and obstacle course.
Study: NCT01371396

Intervention type: OTHER
Group type: OTHER
Intervention: Low-fat diet
Description: The subject will consume a diet that is calorically restricted to cause at least a 6% body weight loss over 4 months. Fat will make up less than 30% of dietary energy.

Intervention type: OTHER
Group type: OTHER
Intervention: Low-fat diet
Description: The subject will consume a diet that is calorically restricted to cause at least a 6% body weight loss over 4 months. Fat will make up less than 30% of dietary energy.

Intervention type: OTHER
Group type: OTHER
Intervention: Low-carbohydrate diet
Description: The diet will be restricted in energy to cause at least a 6% loss of body weight over a 4 month period. Carbohydrate will provide less than 40% of total dietary energy.

Intervention type: OTHER
Group type: OTHER
Intervention: Low-carbohydrate diet
Description: The diet will be restricted in energy to cause at least a 6% loss of body weight over a 4 month period. Carbohydrate will provide less than 40% of total dietary energy.
Study: NCT02606643

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Slight traction
Description: Slight traction will be applied to the balloon catheter

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Foley Catheter to no traction
Description: Foley Catheter to no traction
Study: NCT03219723

Intervention type: DRUG
Intervention: Vonoprazan
Description: Vonoprazan tablets

Intervention type: DRUG
Intervention: Amoxicillin hydrate
Description: Amoxicillin hydrate (potency)

Intervention type: DRUG
Intervention: Clarithromycin
Description: Clarithromycin (potency)

Intervention type: DRUG
Intervention: Metronidazole
Description: Metronidazole
Study: NCT02631408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Locally, intrawound applied vancomycin powder
Study: NCT03122509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: 1500 mg durvalumab via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: 1500 mg durvalumab via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tremelimumab
Description: 75 mg tremelimumab via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tremelimumab
Description: 75 mg tremelimumab via IV infusion

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Description: Radiotherapy (RT) will be performed using external beam ionizing radiation as standard therapy in accordance with institutional standard practice.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ablation
Description: Ablation will be performed percutaneously under image guidance as standard therapy at the discretion of the interventional radiologist in accordance with institutional standard practice.
Study: NCT04429711

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ivermectin Oral Product
Description: 3mg Capsules, 12-15mg/ day for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin Oral Product
Description: 3mg Capsules, 12-15mg/ day for 3 days
Study: NCT04815941

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soft ball tissue release exercises
Description: Exercise program were given to patients with low back pain secondary to hip muscle tightness using soft balls, i.e. tennis balls plus core stability exercises.~3 days a week for four weeks.
Study: NCT01075529

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: fluoxetine
Description: fluoxetine 20 mg/d
Study: NCT03959514

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NovoRapid
Description: Rapid acting prandial insulin aspart

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NovoRapid
Description: Rapid acting prandial insulin aspart

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NovoRapid
Description: Rapid acting prandial insulin aspart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fiasp
Description: Fast acting prandial insulin aspart

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fiasp
Description: Fast acting prandial insulin aspart

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fiasp
Description: Fast acting prandial insulin aspart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AT247
Description: Ultra rapid acting prandial insulin aspart

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AT247
Description: Ultra rapid acting prandial insulin aspart

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AT247
Description: Ultra rapid acting prandial insulin aspart
Study: NCT03501498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: Alters intestinal transit time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Senna
Description: Alters intestinal transit time.